The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Redx Pharma identifies drug development candidate for leukaemia program.....           NBE Therapeutics, Sotio partner to develop next-generation antibody-drug conjugates.....           Theravance and Mylan?s COPD treatment shows benefits in phase 3 trials.....           Sanifit starts first clinical trial of SNF472 in patients with calciphylaxis.....           Amgen's Xgeva matches zoledronic acid in phase 3 trial in multiple myeloma-related bone complications.....           Remicade patients are OK to switch to Celltrion's biosim, study shows, as Pfizer gears up for U.S. rollout.....           Oncologists knock ICER's lung cancer cost-effectiveness review.....           Hot Tecentriq start stands out in 'decent' Q3 for Roche.....           Senator blasts DOJ's 'unacceptable' deal with Mylan, urges AG to dig deeper.....           Eli Lilly's sarcoma newcomer Lartruvo joins burgeoning oncology lineup.....           Eiger doses first patient in phase 2 LIMT HDV study.....           Sun Pharma, ICGEB partner to develop dengue vaccine.....           SOBI003 receives EC orphan designation to treat mucopolysaccharidosis type IIIA.....           Eiger doses first patient in phase 2 LIMT HDV study.....           FDA approves Lilly's LARTRUVO in combination with doxorubicin for soft tissue sarcoma.....           Merck's letermovir succeeds in preventing CMV infection in phase 3 study.....           Domain Therapeutics creates new company to stop Parkinson?s disease progression.....           Merck primes the market for its biosims with online effort targeting docs, patients.....           Teva, Regeneron won't touch blockbuster pain market with fasinumab, analyst predicts.....           Lobby group links antibiotic resistance to 'dirty' drug factories, and Aurobindo is a culprit.....           Card-carrying pharma reps? Chicago eyes licensing for painkiller promoters.....           Pricing blame game continues: OptumRx CEO says pharma's using hikes to fuel profits.....           FDA approves Genentech?s Tecentriq for metastatic non-small cell lung cancer.....           Clinigen expands operations into Japan.....           LLS launches collaborative clinical trial for acute myeloid leukemia.....           Shire's ONIVYDE approved in Europe for pancreatic cancer.....           CDC calls on doctors to pitch HPV shots as cancer prevention, not STD protection.....           Those risk disclosures on drug websites? People don't read them, study says.....           Depomed strikes unexpected deal with activist Starboard, adding J&J, Abbott vets to board.....           Stay calm, investors. J&J has a 'readiness plan' in place for Remicade biosim launch.....           Novartis, late to the Advair generics party, urges FDA to block rival copycats.....           Pfizer loads up for Remicade biosim launch, with $4.5B J&J brand in its sights.....           Medicare formularies add to the squeeze on key Novo Nordisk, Sanofi insulins.....           Roche's Tecentriq scores lung cancer nod, setting up 3-way battle with Merck, BMS.....           FDA places clinical hold on Regeneron and Teva?s pain drug trial.....           Pfizer plans to launch REMICADE biosimilar in US in November.....           Sofinnova closes latest venture capital fund at $650m.....           FDA's ODE-I denies PTC Therapeutics' DMD drug appeal.....           Antegrin and Cascadia merge to form Indalo Therapeutics.....           CHMP recommends marketing approval for Ferring's Rekovell for use in controlled ovarian stimulation.....           GSK backs controversial flu tracker in Theraflu launch deal with Weather Channel.....           Japan seeks hefty cut to blockbuster Opdivo price as officials pull back the reins on health spending.....           Clinton campaign's 'war with pharma!!' went official with last year's stock-busting tweet: WikiLeaks.....           Valeant defends its latest round of price increases--but critics aren't buying it.....           Sanders rallies for California drug pricing crackdown that pharma's eager to defeat.....           CHMP issues positive opinion for BMS? Opdivo in Hodgkin lymphoma.....           Tetraphase doses first patient in phase 3 trial of Eravacycline in cIAI.....           Zucara signs licensing deal with CDRD for therapeutic drug candidate.....           Clementia unveils results from phase 2 trial of palovarotene to treat FOP patients.....           Virtus sues FDA for clearing potassium chloride market of competition.....           Would Teva buy Korea's Celltrion to beef up in biosimilars? It wouldn't say no.....           Allergan adds actresses, Olympian, supermodel to #ActuallySheCan female empowerment push.....           Astellas crowns virtual reality anxiety management tool in 'Shark Tank'-style challenge.....           Astellas Oncology awards top ideas in its non-treatment cancer innovations contest.....           Restasis-maker Allergan recruits actress Marisa Tomei to drive dry eye awareness.....           Rutgers pharmacist fellows to get hands-on experience at McCann Health with first-of-kind program.....           TransThera raises $10m financing to develop Novel NCE Drugs.....           Trevi Therapeutics unveils positive results from phase 2 trial in prurigo nodularis.....           UK MHRA approves continued enrollment in BioMarin?s phase 1/2 study of BMN 270.....           Mylan's next problem? A shareholder suit demanding damages.....           NICE snubs J&J's Imbruvica, this time in Waldenstrom's macroglobulinaemia.....           True North?s TNT009 gets FDA orphan drug status to treat autoimmune hemolytic anemia.....           True North?s TNT009 gets FDA orphan drug status to treat autoimmune hemolytic anemia.....           VBL Therapeutics unveils plans to build new manufacturing facility in Israel.....           U.S. rep's new drug pricing bill proposes Clinton-style panel to punish 'bad actors'.....           Pfizer's Lyrica patent appeal fails in U.K., endangering bid to protect $5B med.....           AZ taps 3SBio to help drive sales of diabetes meds Byetta, Bydureon in China.....           Merck KGaA expects new products to step up big time through 2022.....           Regeneron inks $315M development pact to keep Eylea sales flowing.....           Pharma takes an average 35% hit on list price in Medicare Part D: Report.....           Deal-hungry Pfizer will likely overpay for M&A, analyst predicts.....           RXi Pharmaceuticals signs option deal to buy MirImmune.....           BIOCAD Biotechnology begins phase 2 clinical trials of psoriasis drug.....           Regenicin schedules pre-IND meeting with FDA for new autologous cultured skin substitute.....           ProMetic's PBI-4050 significantly reduces liver fibrosis in alström syndrome patients.....           AMAG Pharmaceuticals achieves key milestones in next generation development programs.....           FDA grants QIDP and fast track designations to Viamet?s VT-1161 to treat RVCC.....           UPDATED: 'Random,' 'unpredictable' drug price hikes send costs skyward at U.S. hospitals, report says.....           IBM makes Watson technology available to US employees fighting cancer.....           Countering Xarelto critics, FDA backs clot buster's benefits despite study's faulty device.....           IPG Mediabrands launches Healix media buying agency for pharma clients across agency network.....           Boehringer's Vargatef comes up one endpoint short in colorectal cancer effort.....           Novartis adds new chemo-topping data to Zykadia marketing arsenal.....           Merck's diabetes blockbuster Januvia boards pay-for-performance train with Aetna deal.....           'Random,' 'unpredictable' drug price hikes send costs skyward at U.S. hospitals, report says.....           Departing Novo chief wins 'best CEO' nod again, and Biogen's grabs laurels, too.....           FDA grants priority review to Genentech?s Lucentis' sBLA for Myopic Choroidal Neovascularization.....           Transgene partners with Merck, Pfizer for head and neck cancer trial.....           FDA grants priority review to Genentech?s Lucentis' sBLA for Myopic Choroidal Neovascularization.....           TFS buys dermatology specialist SCIderm.....           Pfizer's drug improves survival in kidney cancer study.....           Nymox unveils successful phase 3 long-term fexapotide repeat injection BPH trial results.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
PharmSci 2016 Conference - Chair's review

The Chair of the Academy of Phamaceutical Sciences, Dr Linda Hakes, gives a brief review of the 7th APS International PharmSci Conference, held in Glasgow on 5-7 September 2016.

"2016 has come to an end and although I admit that I am probably biased, I think it was a fantastic three days. The venue, the Technology and Innovation Centre at Strathclyde University, was well equipped to handle the conference and the facilities are modern and efficient.

All of the conference sessions (as far as I could tell) were well attended and the plenary lectures were all excellent, covering topics ranging across the spectrum of pharmaceutical sciences, embracing chemistry, pharmacology, medical devices, formulation, pharmacokinetics and spectroscopy.

A highlight of the social side was the Civic Reception in the City Chambers, a magnificent building on George Square, where we were warmly welcomed by the Bailey Steward on behalf of the Lord Provost of Glasgow.






As always the Black Tie Dinner was a great success and we were pleased to have Prof. Sandy Florence as guest speaker. Again, the venue was truly impressive – the Barony Hall.





To sum up, I believe we enjoyed a conference full of good science, excellent networking opportunities, and highly enjoyable social events. If you weren’t there, why not make a note for next year –
Tuesday 5 - Thursday 7 September 2017 at the University of
Hertfordshire .

See you there!"

Latest News
APS thanks retiring Board members and welcomes Yvonne Perrie and Michael Leane as newly appointed Board members
At the AGM on 5 September, held during the PharmSci conference at the Technology and Innovation Centre at Strathclyde University, we formally thanked our two retiring Board members, Richard Storey and Claire Thompson, for all their hard work and support of APS over several years of service. Claire has been an enthusiastic Board member who has been a strong advocate for pharmaceutical science and has been very engaged in outreach to universities, students and young scientists. Richard Storey has served not only as a Board member but has also been our Treasurer for many years, a task which has had many challenges which he has managed in a calm and professional manner. We are very grateful to both of them and hope that they will remain active members and supporters of APS.. . At the AGM we also ratified the selection of Yvonne Perrie (Strathclyde University) and Michael Leane (BMS) as the incoming Board members. We warmly welcome them to the Board and look forward to working with them.
APS Symposium on the Digital Design of Drug Products
MONDAY, 13 JUNE 2016
APS Symposium on the Digital Design of Drug Products 1st July 2016, University of Leeds. The design of new medicinal products is a risky and lengthy process. Current approaches utilise a make and test philosophy to understand processing risk. This requires large amounts of materials and knowledge is often limited by short development timelines and availability of input materials. Hence formulations are often developed that merely accommodate variability in drug substance rather than making it an opportunity and thus a heavily over-engineered formulation and process can be produced. The area of digital design has the opportunity to revolutionise the development and manufacturing of new medicines by utilising both mechanistic and big data approaches to produce holistic models for our processes. This will allow optimal processes and materials to be produced which will permit more rapid development and result in improved robustness of manufacturing processes. This event brings together the concept of materials engineering with state of the art knowledge around modelling of materials and processes. It will provide information around initiatives in the pharmaceutical arena where data sharing is helping to produce better guidelines for processes. An opportunity will also be provided to learn about the recently £24M funded ADDoPT (Advanced Digital Design on Pharmaceutical Therapeutics) project which is aimed to provide new tools to the industry in the area of materials manufacture and processing. The meeting is organised by the Academy of Pharmaceutical Sciences but is kindly facilitated by BACG and CGOM. It is a must attend for scientists and leaders in the pharmaceutical development and manufacturing sector as well as an opportunity for other manufacturing industries to learn about new developments that could be adopted on their processes. For more details please contact Registration for the APS Symposium is now open. Register here: On Thursday evening, before the APS Symposium, Tommy Dolan will be giving an evening lecture on “The Future of Medicines Manufacture: Towards Digital Design”. The Conference dinner will also be taking place on Thursday evening. Expressions of interest for the evening lecture series will be opened closer to the event but the conference dinner and accommodation at the University of Leeds can be booked in addition to your APS registration. Friday 1st July – APS Symposium 09:30 10:00 Registration & Refreshments 10:00 10:05 Welcome – Richard Storey, AstraZeneca/APS Treasurer 10:05 10:45 Keynote #1 – Calvin Sun, University of Minnesota The Materials Science Tetrahedron – The Academic Vision Invited modelling presentations 10:45 11:15 Mojtaba Ghadiri, University of Leeds Particle breakage modelling 11:15 11:45 Jim Litster, University of Sheffield Wet granulation experimental and modelling 11:45 12:15 James Elliott, University of Cambridge Compaction modelling (and DEM solution on DEM modelling) 12:15 13:20 Lunch 13:20 13:50 Industrial Perspective – Kendall Pitt, GlaxoSmithKline The MCS – The Drive From Industry 13:50 14:30 Keynote #2 – Amrit Paudel, Research Centre for Pharmaceutical Engineering Stability by Design 14:30 14:50 Refreshment Break 14:50 15:20 Richard Storey, AstraZeneca Towards the Perfect Particle: What are the important design attributes? 15:20 16:00 Costas Pantelides, Process Systems Enterprise ADDoPT Vision: System-based Pharmaceutics 16:00 16:30 Summary and Close
APS and RPS Awards Announcement
APS Innovative Science Award Lecture 2016. The Academy of Pharmaceutical Sciences present the Innovative Science Award and invite pharmaceutical scientists to submit an application. Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the Innovative Science Award Lecture on their work at APS PharmSci 2016. Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 500 words, focussing on its importance to the pharmaceutical industry. Entries should be submitted via email to Alan Ramsay at including ‘Innovative Science Award 2016’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel. Closing Date for Entries 31st May 2016. . 2016 Royal Pharmaceutical Society Science Award Applications are invited for the 2016 Royal Pharmaceutical Society Science Award. The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the RPS Award Lecture on their work at the 7th Academy of Pharmaceutical Sciences International PharmSci Conference on the 7th September 2016. Applications are welcome from scientists world-wide who are working in a pharmaceutical or allied discipline in industry or academia. With up to 10 years experience at post-doctoral level in September 2016, applicants must have a proven record of independent research and published work that shows outstanding promise. Applicants are invited to submit the following details by 20th May 2016:. Full CV detailing personal information, past and present appointments, research responsibilities and published work. List of research students who have worked for the applicant and their thesis titles and dates, plus any other instances of research collaborations. Details of research grants awarded and the candidate’s role. Invitations to speak at conferences in the UK and overseas, lecture or symposium titles and names of awards. A brief resume of two pages should also be submitted with the CV, indicating discoveries made. Please note copies of publications are not required. Applications should be made by 20th May 2016 preferably by email ( or by post to: Jayne Lawrence, Chief Science Advisor Royal Pharmaceutical Society 66 East Smithfield, London, E1W 1AW.
APS Manufacturing Classification System
TUESDAY, 10 MAY 2016
Be Part of a Successful Global Partnership –APS Manufacturing Classification System . 'Pharmaceutical Sciences: Improving World Health'. Monday 5th – Wednesday 7th September 2016 at the Technology and Innovation Centre, University of Strathclyde, Glasgow. A roundtable session has been organised on Tuesday 6th September at 12.15-13.30, co-chaired by Kendal Pitt (GSK) and Gavin Reynolds (AstraZeneca) giving you the opportunity to input into the Manufacturing Classification System (MCS) and its implementation.. The MCS is a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the Active Pharmaceutical Ingredient (API) and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing based on "ideal" ranges for API physical properties and therefore indicate how robust a manufacturing process is likely to be in relation to those properties.. This represents a very successful APS-driven Industry collaboration which has already resulted in a publication entitled “‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms”. This was the most downloaded article in Pharmaceutical Development & Technology of 2015 and the cross-industry authors have been commended for their contribution to Pharmaceutical Development & Technology.. For more information and to register for the conference, go to on or before 31st July 2016 to take advantage of the Early Bird Rates for the conference..
Follow us
Upcoming Events
MIBio 2016: Stability of biopharmaceuticals
9 November 2016
APS Industrial Insights 2017
20 - 21 April 2017
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.